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Abstract
Isolated invasive Aspergillus tracheobronchitis (iIATB) is an uncommon clinical form of invasive Aspergillosis in which Aspergillus infec-
tion is limited entirely or predominantly to the tracheobronchial tree. In the present study, we retrospectively analyzed the medical
records of 19 patients who had histological documented iIATB in the Department of Respiratory Medicine of Changhai Hospital
between October 2000 and February 2008. Malignancy was the most common underlying disease, which existed in 14 patients
(73.7%) in our series. Most patients had impaired airway structures or defence functions, whereas the systemic immune status was
relatively normal. Only three patients (15.8%) had neutropenia. The clinical manifestations and chest radiograph were nonspeciﬁc. We
classiﬁed iIATB into four different forms according to the bronchoscopic features of intraluminal lesions: superﬁcial inﬁltration type
(Type I, n = 4), full-layer involvement type (Type II, n = 2), occlusion type (Type III, n = 6) and mixed type (Type IV, n = 7). Type IV
was the largest group in our study, followed by Type III. All patients with iIATB of Type IV had deﬁnite airway occlusion. Fourteen
patients (73.7%) had a good response to antifungal treatments and ﬁve (26.3%) died as a result of the progression of Aspergillosis, all
of whom had full-layer invasion of the involved bronchi. In conclusion, we found that iIATB could occur in moderately or non-
immunocompromised patients with impaired airway structures or defence functions and may be an early period of invasive pulmonary
Aspergillosis. Most of the iIATB patients had a favourable prognosis with early diagnosis and effective antifungal treatment. The
morphological features of intraluminal lesions might be of prognostic value.
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Introduction
Invasive pulmonary Aspergillosis (IPA) is a severe disease that
is traditionally reported in patients with haematological malig-
nancy with neutropenia, in bone marrow or in solid organ
transplant recipients [1–5], as well as in those receiving corti-
costeroid therapy [6]. In most studies, the mortality of IPA
patients was higher than 70% [7]. In some reports, the ﬁgure
is even up to 100% [8]. Aspergillus tracheobronchitis (ATB), as
a sub-entity of IPA, is an uncommon clinical form in which
Aspergillus infection is limited entirely or predominantly
conﬁned to the tracheobronchial tree. It was ﬁrst described
as tracheobronchial inﬂammation and/or excess mucus
production caused by a saprophytic growth of hyphae or
sporing on the surface of bronchial mucosa, without invasion
of mucosa as revealed by biopsy [9]. In 1970, Young et al.
[10] reviewed 98 cases of histologically documented Aspergil-
losis, of which eight had fungal infection of the tracheobron-
chial wall; in ﬁve individuals, the infection was apparently
limited to this site. However, invasive forms of ATB had not
been fully described until 1991 by Kramer et al. [11]. These
authors reported three cases of tracheobronchitis after
heart-lung and lung transplantation with deep mucosal ulcera-
tion and histologic evidence of invasive Aspergillosis. Invasive
ATB (IATB) had been documented in a few case reports.
Lung parenchyma or other organs were usually involved
together with IATB in most of these cases, whereas there
were few patients who had isolated invasive (iIATB)
Aspergillus tracheobronchitis. The present study aimed to
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analyze the underlying conditions, risk factors, clinical features
and endoscopic characteristics of iIATB and to specify the
prognosis of these patients. To our knowledge, this is the
largest study concerning iIATB conducted so far.
Materials and methods
Medical records of 19 patients who had histologically docu-
mented iIATB in the Department of Respiratory Medicine of
Changhai Hospital, Second Military Medical University,
between October 2000 and February 2008, were retrospec-
tively analysed. The Institutional Review Board of Changhai
Hospital approved this study and, because of the retrospec-
tive nature, patient consent was not needed. Isolated IATB
was deﬁned as the isolation of Aspergillus species from endo-
bronchial specimens, the presence of one or more endo-
bronchial lesions without an alternative diagnosis and
without clinical, radiographic or histopathological evidence of
invasive parenchymal disease [4]. All patients had records of
abnormal bronchoscopic ﬁndings and positive tracheobron-
chial biopsy results.
Demographic data, underlying diseases, risk factors, clinical
presentations, laboratory results and histopathological and
bronchoscopic ﬁndings were extracted from medical
records. Medications and outcomes were also analysed.
Treatment was considered to be efﬁcacious after micro-
biological eradication (i.e. at least two sequential negative
cultures), resolution of clinical manifestations and healing or
improvement of endobronchial abnormalities attributable
to Aspergillus infection. Failure encompassed progression
of Aspergillosis or death as a result of iIATB. All patients
were followed for at least 6 months after the diagnosis of
iIATB.
According to the bronchoscopic ﬁndings of these patients,
four types of iIATB were established: superﬁcial inﬁltration
type (Type I); full-layer involvement type (Type II); occlusion
type (Type III); and mixed type (Type IV). A detailed descrip-
tion of the relevant bronchoscopic features and a represen-
tative illustration of each type is provided in Table 1 and
Fig. 1, respectively. Intraluminal lesions caused by diseases
other than Aspergillus infection were excluded when classiﬁ-
cation was performed.
Results
The median age of these nineteen patients was 50 (range
36–75) years. Six of the patients were women and 13 were
men. As noted in Table 2, all patients had underlying diseases
except two, who were diagnosed with primary iIATB. Malig-
nancy was the most common underlying disease, which had
been seen in 14 cases (73.7%): 13 cases of solid tumours and
one case of non-Hodgkin’s lymphoma. Trachobronchial
tuberculosis and traumatic tracheostenosis were seen in two
(10.5%) and one (5.3%) patient, respectively. Possible risk
factors associated with iIATB were analysed and are shown
in Table 3.
Cough (n = 18, 94.7%) was the most common symptom,
followed by exertional dyspnoea (n = 10, 52.6%). Fifteen
patients with cough had complained of white or purulent
sputum and three had a nonproductive cough. Bloody
phlegm or mild hemoptysis was observed in ﬁve patients
(26.3%). Other clinical manifestations included fever (‡38C)
in four patients (21.1%), wheezing in three patients (15.8%),
and night sweats in one patient (5.3%). The most common
radiographic ﬁnding was trancheobronchial stenosis (n = 8,
42.1%). Two patients had an image of pulmonary atelectasis.
Eleven patients (57.9%) did not show any new radiographic
abnormalities when symptoms associated with iIATB
appeared.
Bronchoscopy was performed once the diagnosis of
Aspergillus infection was suspected. A total of twenty iso-
lates of Aspergillus species had been obtained from biopsy
specimens (n = 19) or other respiratory tract specimens
(n = 10), including sputum, tracheal aspirate or bronchial
TABLE 1. Proposed classiﬁcation of isolated invasive Aspergillus tracheobronchitis
Classiﬁcation Bronchoscopic features References
Type I: superﬁcial inﬁltration type Inﬂammatory inﬁltration, mucosa hyperaemia, mucosa hydropsia and superﬁcial ulcer which is
conﬁned to the mucosa and submucosa; mild plaques of pseudomembrane formation without
obvious airway obstruction or deeper tissue invasion
4,10,11,18,25,34–36
Type II: full-layer involvement type Tracheobronchial lesions inﬁltrating through the matrix layer of bronchi, often with substantial and
deep ulceration, extensive tissue necrosis with cartilage invasion and destruction of normal
airway structures
4,18,19,21a,34,35,37,38
Type III: occlusion type Airway obstruction or constriction ‡50% of the original calibre of involved bronchi caused by
extensive pseudomembrane formation, polypoid granulation or necrotic tissues as a result of
Aspergillus infection, without deﬁnite proof of full-layer invasion
2,4,10,20,21a,38–40a
Type IV: mixed type Two or more different forms of typical bronchoscopic features coexisting at the time of diagnosis 4,11,19,21a,22a,26,27,29–31,32a,33
aAutopsy diagnosis.
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lavage ﬂuid. As shown in Table 2, Aspergillus fumigatus was
isolated from 14 (73.7%) patients and was the most com-
mon pathogen. The other species included Aspergillus ﬂavus
(n = 4), Aspergillus terreus and Aspergillus niger (one case
each). The trachea was the most frequently involved site
(n = 15, 78.9%). According to our bronchoscopic classiﬁca-
tion, the group of Type IV, which included seven cases
(36.8%), was the largest group in this study, followed by
Type III (n = 6, 31.6%). It was found that all patients with
iIATB of Type IV had deﬁnite airway occlusion. Five of
them had full-layer involvements and two had superﬁcial
inﬁltrations concomitantly. The number of patients with iI-
ATB of Type I and Type II was four (21.1%) and two
(10.5%), respectively.
Seventeen patients were given antifungal treatment orally
or intravenously and two (subjects 13 and 15; Table 2) were
given local applications. The mean treatment duration was
25 (range 8–47) days. The initial therapy included itracona-
zole [11 cases, 200 mg every 12 h intravenously (i.v.) for
2 days, then 200 mg/day i.v.; or 200 mg every 12 h per oral],
liposomal amphotericin B (three cases, 3–5 mg/kg/day i.v.),
amphotericin B (two cases, nebulization 5–10 mg twice a
day), voriconazole (two cases, 250 mg every 12 h i.v. for
1 day, 200 mg every 12 h i.v. thereafter; or 200 mg every
12 h per oral) and caspofungin (one case, 70 mg at day 1 i.v.
and 50 mg/day thereafter). Intermittent bronchscopic inter-
vention, including electrocauterization, cryotherapy, mechani-
cal debridement and intraluminal antifungal instillation
(amphotericin B, 5 mg twice a week) were performed as
adjunctive treatments in most patients.
Five patients died of progression of iIATB, three of which
belonged to Type IV and two to Type II. Efﬁcacious treat-
ment had been achieved in all the other 14 patients (73.7%)
although two of them died of primary malignant diseases
within 6 months after antifungal treatment. The mortality
associated with iIATB was 26.3%.
Discussion
Aspergillus spp. are saprophytic ﬁlamentous fungi that are
widespread in the environment and are responsible for a
(a) (b)
(d)(c)
FIG. 1. Characteristic bronchoscopic manifestations of isolated invasive Aspergillus tracheobronchitis. (a) Type I. Inﬂammatory inﬁltration, mucosa
hyperaemia and plaques of pseudomembrane formation in the lumens without obvious airway occlusion. (b) Type II. Deep ulceration of the
bronchial wall. (c) Type III. Signiﬁcant airway occlusion by thick mucous plugs full of Aspergillus without deﬁnite deeper tissue invasion. (d) Type
IV. Extensive tissue necrosis and pseudomembrane formation in the lumen with airway structures and severe airway occlusion.
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broad spectrum of illnesses, from saprophytic colonization of
the bronchial tree to rapidly invasive and disseminated dis-
eases. Isolated IATB is an uncommon form of IPA with fungal
infection localized in the tracheobronchial tree. In the pres-
ent study, we retrospectively analysed the records of 19
patients with iIATB in our department and found that the
susceptible population, clinical characteristics and prognosis
of iIATB were different from those of IPA as reported previ-
ously [1–8]. We also attempted to classify iIATB into four
types according to the bronchoscopic characteristics and
found that the morphological features of the intraluminar
lesions might predict the prognosis of these patients.
According to the criteria for invasive fungal infections
deﬁned by the European Organization for the Research and
Treatment of Cancer/Mycoses Study Group, host factors for
the acquisition of invasive diseases were taken into account
[12]. Most of the IATB cases reported in the literature were
observed in patients with severely immunocompromised
status, including lung or bone marrow transplant recipients
[1–4,8,13–18], patients with AIDS, granulocytopenia [19,20],
or haematological and lymphoreticular malignancies.
Although rarely, the disease has also been seen in immuno-
competent patients [18,21–26]. In our series, 13 patients had
solid tumours and one suffered from haematological carci-
noma. Although most of them had undergone radiotherapy
and/or chemotherapy, only three patients had neutropenia,
which was quite different from the spectrum of patients at
risk of IPA. Noticeably, seven patients (36.8%) had original
airway constriction, which had not been reported before as
a risk factor for invasive Aspergillosis. Airway structures and
mucociliary clearance are impaired and hypoxaemia is usually
obvious in these patients, which will attenuate the defense
functions of airways and lead to opportunistic infections,
whereas a relatively normal systemic immune status will
prevent the spread of infection and substantially contribute
to the localization of the disease.
IATB has been described as a less well recognized form of
invasive disease that is potentially lethal and requires early
clinical detection [27]. Many published cases of IATB had not
been diagnosed until post mortem [18]. Deﬁning the line
between invasion by Aspergillus spp. and their status as com-
mensals within the airways is sometimes difﬁcult, especially
in moderately and non-immunocompromised patients [11].
Kramer et al. [11]. have classiﬁed bronchial Aspergillosis into
four forms, mainly based on clinical-pathological features of
the intraluminal lesions, among which ‘ulcerative tracheo-
bronchitis’ and ‘pseudomembranous tracheobronchitis’ indi-
cate invasive airway infection due to Aspergillus, whereas the
other two, ‘tracheobronchitis’ and ‘obstructing bronchial
Aspergillosis’, indicate non-invasive bronchial Aspergillosis
caused by Aspergillus colonization [11,28]. However, the
coexistence of various pathological features, such as
occlusion, ulceration and pseudomembranes, has often been
observed in IATB patients [4,11,19,21,22,26,27,29–33]. There
are also reports of some histologically diagnosed IATB
patients who showed mild superﬁcial mucosa erosion or
necrosis only [4,10,11,18,25,34–36]. In 1993, Kemper et al.
[18] proposed the need for a classiﬁcation system for
Aspergillus airway disease that provides clinically meaningful
information based on pathophysiological mechanisms,
histological features, and the potential for progression, which
is correlated with clinical outcome. However, no ideal classi-
ﬁcation has been proposed so far. Because bronchoscopy is
the most direct and effective method in iIATB diagnosis, we
propose our classiﬁcation of iIATB mainly according to the
bronchoscopic morphology of the intraluminal lesions. In our
classiﬁcation, patients with airway occlusion ‡50% of the
original calibre of involved bronchi are all classiﬁed into Type
III (i.e. the occlusion type), regardless of the causes of
the occlusions. The feature of Type I is much like ‘tracheo-
bronchitis’ except for its invasive nature. The delineation of
Type II is analogous to ‘deeper ulcerative tracheobronchitis’.
Type IV pertains to patients with two or more characteristic
lesions. We also reviewed the published cases of iIATB
which had concrete descriptions of intraluminal lesions under
endoscopy or at autopsy and attempted to classify them
according to our classiﬁcation (Table 1). Five patients in our
series died of uncontrolled iIATB, three of them had iIATB
of Type IV and two had iIATB of Type II. It is noted that all
ﬁve patients had full-layer invasion of the involved bronchi by
Aspergillus. We deem that, as a localized entity, iIATB may be
an early stage of Aspergillus invasion and that it may progress
to more extensive and invasive infection without early detec-
tion and effective treatment. The outcome of our patients
TABLE 3. Risk factors associated with isolated invasive
Aspergillus tracheobronchitis in 19 patients
Risk factor
Number (%)
of patients
Systemic or local (chest) radiotherapy 12 (63.2)
Chemotherapy 8 (42.1)
Airway constrictiona 7 (36.8)
Prior systemic corticosteroid therapy (‡3 weeks) 5 (26.3)
Prior inhalated corticosteroid therapy (‡2 weeks) 4 (21.1)
Hypoproteinaemia (<30 g/L) 4 (21.1)
Prior antibiotic therapy(‡2 weeks) 3 (15.8)
Neutropenia (<500 neutrophils/mm3 for >10 days) 3 (15.8)
None 2 (10.5)
aThe causes of airway constriction (determined as <75% of the normal calibre
of the airway involved), included intraluminal neoplastic growth (n = 1), com-
pression by tumours or intumescent lymph nodes (n = 3) and scarring or mol-
malacice of the bronchial wall as a result of endobronchial tuberculosis (n = 2)
or trauma (n = 1).
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suggests that, in iIATB, full-layer involvements of the bronchi
may be indicative of a more aggressive period of the disease
and of poorer prognosis. Considering the small sample size
of our study, the relationship between the iIATB types of
our classiﬁcation and the prognosis for iIATB patients
remains to be conﬁrmed by further investigations.
In the absence of deﬁnite treatment standards concerning
ATB until 2008 in the proposal of the Infectious Diseases
Society of America [41] guidelines for Aspergillus infections,
the antifungal treatments of our patients were empirical. We
emphasize the importance of combining bronchoscopic inter-
vention and antifungal therapy in the treatment of iIATB
because of the immediate effects of intervention to relieve
obstruction, hemostasis and symptom resolution. Kemper
et al. [18] summarized the pertinent features of patients with
IATB documented in the literature subsequent to 1962 and
reported that only 21% (6/28 cases) had been ‘cured’ of their
disease. However, the patients with parenchymal lung involve-
ment had not been excluded in their study. In 2001, Mehrad
et al. [4] concluded from the published series available that
82% of lung transplant recipients with iIATB had a favourable
outcome with appropriate treatment. In our series, efﬁcacious
treatment was achieved in nearly 74% of the patients, which
indicates a favourable prognosis for those iIATB patients
experiencing early diagnosis and effective management.
In this large clinical study, we found that iIATB, which
occurs mostly in patients with impaired local defense functions
of the airways, regardless of their systemic immune statuses,
might correspond to an early period of IPA. Clinical mani-
festations in patients with iIATB were unspeciﬁc and bron-
choscopy was essential for both early diagnosis and treatment.
We classiﬁed iIATB into four different types, mainly based on
the morphological features of intraluminal lesions, and found
that airway occlusion was the most common abnormality in iI-
ATB, whereas full-layer invasion of the involved bronchi might
indicate advanced disease and poor prognosis.
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